| Serial Number | 79198534 |
| Word Mark | RELIEF THERAPEUTICS |
| Filing Date | Wednesday, August 3, 2016 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 3, 2018 |
| Registration Number | 5505300 |
| Registration Date | Tuesday, July 3, 2018 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, April 17, 2018 |
| Description of Mark | The mark consists of the stacked wording "RELIEF THERAPEUTICS" with a stylized tree design partially set on top of the letter "R" in "RELIEF". |
| Goods and Services | Pharmaceutical and veterinary products, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; diagnostic products for medical use, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medicinal preparations and substances, namely, protein supplements, peptides from synthetic sources or extracted from natural organisms for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation, and small chemical molecules from synthetic or natural sources for the treatment of pulmonary affections, diabetic complications, neuropathies, allergies, and inflammation ; biochemical preparations for medical or veterinary use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biological and chemical reagents for medical or veterinary use; biological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; chemical preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological preparations for medical use, namely, for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biotechnological products for medical use, namely, prescription drugs for the treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; medical diagnostic products, namely, diagnostic preparations and reagents for the diagnosis of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; biomarkers for medicine, namely, diagnostic biomarker reagents for medical purposes |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Business consulting; project management services for others for business purposes; business consultancy services; compilation and management of computerized databases and central data files in the field of medicine; compilation of statistics; collection and systematization of data in a central file; business information, namely, provision of commercial information in the field of pharmaceutical products and provision of commercial information for consumers relating to medical and scientific research in the field of pharmaceutical products |
| NOT AVAILABLE | "RELIEF THERAPEUTICS" |
| Goods and Services | Scientific and technological services, namely, scientific and pharmaceutical research, testing the efficacy, safety and tolerability of pharmaceuticals, and pharmaceutical drug development as well as new product research and design relating thereto; industrial analysis and research services in the field of pharmaceuticals, medical diagnostic preparations, and biotechnology; scientific research and development and medical research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; research and development in the field of biotechnology; research in the fields of chemistry and biology; research in the field of biochemistry; scientific research for medical purposes; research and development in the field of diagnostic preparations; product development consulting; research and development of products; pharmaceutical research and development services; computer-aided scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; conducting of scientific feasibility studies; scientific analyses in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; scientific research, testing and analysis services in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; services provided by consultants in the field of scientific and industrial research, namely, research and development of new therapeutic pharmaceutical preparations; preparation of reports relating to scientific research; providing scientific research information in the form of scientific reports; provision of information and data relating to scientific and technological research and development in the field of pharmaceuticals, medical diagnostic preparations and biotechnology; providing research information and results in the fields of biotechnology, science and medicine from an on-line searchable database; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; scientific research services for third parties in the field of biotechnology; design and development of computer hardware and software; development and research of products for third parties; consultancy services relating to biotechnology; analysis services, namely, consulting services in the fields of biotechnology, pharmacotherapy research and development, diagnostics, and pharmaceutical research and development; pharmaceutical and biological development and research services for third parties; clinical research in the field of treatment of diabetic complications, inflammatory diseases, pulmonary affections, neurological diseases, and metabolic diseases; evaluation of pharmaceutical products; research in the field of pharmaceutical products; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; clinical development services, namely, research and development of new therapeutic pharmaceutical preparations; none of the foregoing for clinical trials on safety and effectiveness of drugs, apremilast, drugs for Behçet's disease, or for providing medical and scientific research information in the field of clinical trials |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 23, 2016 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 23, 2016 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, December 23, 2016 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Relief Therapeutics Holding S.A. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | CH |
| Party Name | Relief Therapeutics S.A. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Genève CH-1208 CH |
| Party Name | Relief Therapeutics S.A. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Genève CH-1208 CH |
| Event Date | Event Description |
| Tuesday, December 27, 2016 | APPLICATION FILING RECEIPT MAILED |
| Thursday, December 22, 2016 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, December 23, 2016 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 23, 2016 | ASSIGNED TO EXAMINER |
| Wednesday, December 28, 2016 | NON-FINAL ACTION WRITTEN |
| Thursday, December 29, 2016 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, January 10, 2017 | REFUSAL PROCESSED BY MPU |
| Tuesday, January 10, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, January 27, 2017 | REFUSAL PROCESSED BY IB |
| Monday, July 10, 2017 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, July 10, 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, July 11, 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, July 14, 2017 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, July 14, 2017 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, August 1, 2017 | NON-FINAL ACTION E-MAILED |
| Tuesday, August 1, 2017 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 1, 2017 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, February 1, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, March 28, 2018 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Thursday, February 1, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 2, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 22, 2018 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, February 22, 2018 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, February 22, 2018 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, February 22, 2018 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, March 15, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, March 15, 2018 | NEW REPRESENTATIVE AT IB RECEIVED |
| Wednesday, October 3, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Wednesday, March 28, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, March 28, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, April 13, 2018 | NOTIFICATION PROCESSED BY IB |
| Tuesday, April 17, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 17, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, May 23, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Wednesday, May 23, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, June 8, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Tuesday, July 3, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Friday, October 5, 2018 | FINAL DISPOSITION PROCESSED |
| Friday, October 5, 2018 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, October 26, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, January 20, 2022 | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED |
| Thursday, January 20, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, January 20, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, January 20, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, January 20, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, January 20, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, February 18, 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, August 16, 2022 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Saturday, June 1, 2024 | REGISTERED - SEC. 7 REQUEST ABANDONED |
| Monday, July 3, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Tuesday, March 22, 2022 | TEAS SECTION 7 REQUEST RECEIVED |
| Saturday, April 16, 2022 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Wednesday, August 24, 2022 | POST REGISTRATION ACTION MAILED - SEC. 7 |